Side effects from increased doses of carbamazepine on neuropsychological and posturographic parameters of humans.
Identifieur interne : 001458 ( Main/Exploration ); précédent : 001457; suivant : 001459Side effects from increased doses of carbamazepine on neuropsychological and posturographic parameters of humans.
Auteurs : A. Delcker [Allemagne] ; H. Wilhelm ; D. Timmann ; H C DienerSource :
- European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology [ 0924-977X ] ; 1997.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Analgésiques non narcotiques (administration et posologie), Analgésiques non narcotiques (effets indésirables), Analgésiques non narcotiques (usage thérapeutique), Attention (effets des médicaments et des substances chimiques), Carbamazépine (administration et posologie), Carbamazépine (effets indésirables), Carbamazépine (usage thérapeutique), Femelle (MeSH), Humains (MeSH), Mâle (MeSH), Névralgie essentielle du trijumeau (complications), Névralgie essentielle du trijumeau (traitement médicamenteux), Performance psychomotrice (effets des médicaments et des substances chimiques), Posture (physiologie), Sujet âgé (MeSH), Temps de réaction (effets des médicaments et des substances chimiques), Tests neuropsychologiques (MeSH).
- MESH :
- administration et posologie : Analgésiques non narcotiques, Carbamazépine.
- effets des médicaments et des substances chimiques : Attention, Performance psychomotrice, Temps de réaction.
- effets indésirables : Analgésiques non narcotiques, Carbamazépine, Névralgie essentielle du trijumeau.
- physiologie : Posture.
- traitement médicamenteux : Névralgie essentielle du trijumeau.
- usage thérapeutique : Analgésiques non narcotiques, Carbamazépine.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Mâle, Sujet âgé, Tests neuropsychologiques.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Analgesics, Non-Narcotic (administration & dosage), Analgesics, Non-Narcotic (adverse effects), Analgesics, Non-Narcotic (therapeutic use), Attention (drug effects), Carbamazepine (administration & dosage), Carbamazepine (adverse effects), Carbamazepine (therapeutic use), Female (MeSH), Humans (MeSH), Male (MeSH), Middle Aged (MeSH), Neuropsychological Tests (MeSH), Posture (physiology), Psychomotor Performance (drug effects), Reaction Time (drug effects), Trigeminal Neuralgia (complications), Trigeminal Neuralgia (drug therapy).
- MESH :
- chemical , administration & dosage : Analgesics, Non-Narcotic, Carbamazepine.
- chemical , adverse effects : Analgesics, Non-Narcotic, Carbamazepine.
- chemical , therapeutic use : Analgesics, Non-Narcotic, Carbamazepine.
- complications : Trigeminal Neuralgia.
- drug effects : Attention, Psychomotor Performance, Reaction Time.
- drug therapy : Trigeminal Neuralgia.
- physiology : Posture.
- Adult, Aged, Female, Humans, Male, Middle Aged, Neuropsychological Tests.
Abstract
Patients taking anticonvulsant drugs display a broad spectrum of side-effects. Particularly, in the beginning of treatment and with increasing doses of carbamazepine, side effects such as dizziness, ataxia, drowsiness and reduction of alertness occur, which improve some days after the dose has reached a stable level. Our aim was to find objective parameters for grading these side effects and to differentiate between neurophysiological and neuropsychological side effects of carbamazepine in a clinical situation. Twenty-two patients with trigeminal neuralgia were included for a follow-up study with increasing carbamazepine doses (0 mg to 600 mg). The effect of carbamazepine on postural stability was quantified by posturography. Different neuropsychological tests to study cognitive effects of carbamazepine were performed. The composite equilibrium score showed a significant reduction of postural stability with increasing doses of carbamazepine. In sensory analysis the somatosensory ratio was significantly influenced by increased doses of carbamazepine during the study. Mean reaction time of tonic alertness and physical alertness varied significantly with different doses of carbamazepine. There was a significant influence in patients attention during trail making tests and divided attention tests with increase in carbamazepine. In conclusion our observations show that the rate of change of carbamazepine doses is an important determinant of cognitive and motor functions in the phase of increasing doses.
DOI: 10.1016/s0924-977x(97)00406-9
PubMed: 9213081
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Side effects from increased doses of carbamazepine on neuropsychological and posturographic parameters of humans.</title><author><name sortKey="Delcker, A" sort="Delcker, A" uniqKey="Delcker A" first="A" last="Delcker">A. Delcker</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Essen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, University of Essen</wicri:regionArea><wicri:noRegion>University of Essen</wicri:noRegion><wicri:noRegion>University of Essen</wicri:noRegion><wicri:noRegion>University of Essen</wicri:noRegion></affiliation></author><author><name sortKey="Wilhelm, H" sort="Wilhelm, H" uniqKey="Wilhelm H" first="H" last="Wilhelm">H. Wilhelm</name></author><author><name sortKey="Timmann, D" sort="Timmann, D" uniqKey="Timmann D" first="D" last="Timmann">D. Timmann</name></author><author><name sortKey="Diener, H C" sort="Diener, H C" uniqKey="Diener H" first="H C" last="Diener">H C Diener</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1997">1997</date><idno type="RBID">pubmed:9213081</idno><idno type="pmid">9213081</idno><idno type="doi">10.1016/s0924-977x(97)00406-9</idno><idno type="wicri:Area/Main/Corpus">001454</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001454</idno><idno type="wicri:Area/Main/Curation">001454</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001454</idno><idno type="wicri:Area/Main/Exploration">001454</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Side effects from increased doses of carbamazepine on neuropsychological and posturographic parameters of humans.</title><author><name sortKey="Delcker, A" sort="Delcker, A" uniqKey="Delcker A" first="A" last="Delcker">A. Delcker</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Essen, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, University of Essen</wicri:regionArea><wicri:noRegion>University of Essen</wicri:noRegion><wicri:noRegion>University of Essen</wicri:noRegion><wicri:noRegion>University of Essen</wicri:noRegion></affiliation></author><author><name sortKey="Wilhelm, H" sort="Wilhelm, H" uniqKey="Wilhelm H" first="H" last="Wilhelm">H. Wilhelm</name></author><author><name sortKey="Timmann, D" sort="Timmann, D" uniqKey="Timmann D" first="D" last="Timmann">D. Timmann</name></author><author><name sortKey="Diener, H C" sort="Diener, H C" uniqKey="Diener H" first="H C" last="Diener">H C Diener</name></author></analytic><series><title level="j">European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</title><idno type="ISSN">0924-977X</idno><imprint><date when="1997" type="published">1997</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Analgesics, Non-Narcotic (administration & dosage)</term><term>Analgesics, Non-Narcotic (adverse effects)</term><term>Analgesics, Non-Narcotic (therapeutic use)</term><term>Attention (drug effects)</term><term>Carbamazepine (administration & dosage)</term><term>Carbamazepine (adverse effects)</term><term>Carbamazepine (therapeutic use)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Neuropsychological Tests (MeSH)</term><term>Posture (physiology)</term><term>Psychomotor Performance (drug effects)</term><term>Reaction Time (drug effects)</term><term>Trigeminal Neuralgia (complications)</term><term>Trigeminal Neuralgia (drug therapy)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Analgésiques non narcotiques (administration et posologie)</term><term>Analgésiques non narcotiques (effets indésirables)</term><term>Analgésiques non narcotiques (usage thérapeutique)</term><term>Attention (effets des médicaments et des substances chimiques)</term><term>Carbamazépine (administration et posologie)</term><term>Carbamazépine (effets indésirables)</term><term>Carbamazépine (usage thérapeutique)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Mâle (MeSH)</term><term>Névralgie essentielle du trijumeau (complications)</term><term>Névralgie essentielle du trijumeau (traitement médicamenteux)</term><term>Performance psychomotrice (effets des médicaments et des substances chimiques)</term><term>Posture (physiologie)</term><term>Sujet âgé (MeSH)</term><term>Temps de réaction (effets des médicaments et des substances chimiques)</term><term>Tests neuropsychologiques (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Analgesics, Non-Narcotic</term><term>Carbamazepine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Analgesics, Non-Narcotic</term><term>Carbamazepine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Analgesics, Non-Narcotic</term><term>Carbamazepine</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Analgésiques non narcotiques</term><term>Carbamazépine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Trigeminal Neuralgia</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Attention</term><term>Psychomotor Performance</term><term>Reaction Time</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Trigeminal Neuralgia</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Attention</term><term>Performance psychomotrice</term><term>Temps de réaction</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Analgésiques non narcotiques</term><term>Carbamazépine</term><term>Névralgie essentielle du trijumeau</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Posture</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Posture</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Névralgie essentielle du trijumeau</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Analgésiques non narcotiques</term><term>Carbamazépine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuropsychological Tests</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Sujet âgé</term><term>Tests neuropsychologiques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients taking anticonvulsant drugs display a broad spectrum of side-effects. Particularly, in the beginning of treatment and with increasing doses of carbamazepine, side effects such as dizziness, ataxia, drowsiness and reduction of alertness occur, which improve some days after the dose has reached a stable level. Our aim was to find objective parameters for grading these side effects and to differentiate between neurophysiological and neuropsychological side effects of carbamazepine in a clinical situation. Twenty-two patients with trigeminal neuralgia were included for a follow-up study with increasing carbamazepine doses (0 mg to 600 mg). The effect of carbamazepine on postural stability was quantified by posturography. Different neuropsychological tests to study cognitive effects of carbamazepine were performed. The composite equilibrium score showed a significant reduction of postural stability with increasing doses of carbamazepine. In sensory analysis the somatosensory ratio was significantly influenced by increased doses of carbamazepine during the study. Mean reaction time of tonic alertness and physical alertness varied significantly with different doses of carbamazepine. There was a significant influence in patients attention during trail making tests and divided attention tests with increase in carbamazepine. In conclusion our observations show that the rate of change of carbamazepine doses is an important determinant of cognitive and motor functions in the phase of increasing doses.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9213081</PMID><DateCompleted><Year>1997</Year><Month>09</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0924-977X</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>3</Issue><PubDate><Year>1997</Year><Month>Aug</Month></PubDate></JournalIssue><Title>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</Title><ISOAbbreviation>Eur Neuropsychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Side effects from increased doses of carbamazepine on neuropsychological and posturographic parameters of humans.</ArticleTitle><Pagination><MedlinePgn>213-8</MedlinePgn></Pagination><Abstract><AbstractText>Patients taking anticonvulsant drugs display a broad spectrum of side-effects. Particularly, in the beginning of treatment and with increasing doses of carbamazepine, side effects such as dizziness, ataxia, drowsiness and reduction of alertness occur, which improve some days after the dose has reached a stable level. Our aim was to find objective parameters for grading these side effects and to differentiate between neurophysiological and neuropsychological side effects of carbamazepine in a clinical situation. Twenty-two patients with trigeminal neuralgia were included for a follow-up study with increasing carbamazepine doses (0 mg to 600 mg). The effect of carbamazepine on postural stability was quantified by posturography. Different neuropsychological tests to study cognitive effects of carbamazepine were performed. The composite equilibrium score showed a significant reduction of postural stability with increasing doses of carbamazepine. In sensory analysis the somatosensory ratio was significantly influenced by increased doses of carbamazepine during the study. Mean reaction time of tonic alertness and physical alertness varied significantly with different doses of carbamazepine. There was a significant influence in patients attention during trail making tests and divided attention tests with increase in carbamazepine. In conclusion our observations show that the rate of change of carbamazepine doses is an important determinant of cognitive and motor functions in the phase of increasing doses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Delcker</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilhelm</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Timmann</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Diener</LastName><ForeName>H C</ForeName><Initials>HC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur Neuropsychopharmacol</MedlineTA><NlmUniqueID>9111390</NlmUniqueID><ISSNLinking>0924-977X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018712">Analgesics, Non-Narcotic</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>S</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018712" MajorTopicYN="N">Analgesics, Non-Narcotic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011187" MajorTopicYN="N">Posture</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014277" MajorTopicYN="N">Trigeminal Neuralgia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1997</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1997</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1997</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9213081</ArticleId><ArticleId IdType="pii">S0924-977X(97)00406-9</ArticleId><ArticleId IdType="doi">10.1016/s0924-977x(97)00406-9</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country></list><tree><noCountry><name sortKey="Diener, H C" sort="Diener, H C" uniqKey="Diener H" first="H C" last="Diener">H C Diener</name><name sortKey="Timmann, D" sort="Timmann, D" uniqKey="Timmann D" first="D" last="Timmann">D. Timmann</name><name sortKey="Wilhelm, H" sort="Wilhelm, H" uniqKey="Wilhelm H" first="H" last="Wilhelm">H. Wilhelm</name></noCountry><country name="Allemagne"><noRegion><name sortKey="Delcker, A" sort="Delcker, A" uniqKey="Delcker A" first="A" last="Delcker">A. Delcker</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PosturoV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001458 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001458 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PosturoV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:9213081
|texte= Side effects from increased doses of carbamazepine on neuropsychological and posturographic parameters of humans.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:9213081" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PosturoV1
| This area was generated with Dilib version V0.6.37. |  |